Concerns Over MedPAC’s Impact on Medicare Advantage
One clear example of how a permanent bureaucracy in Washington influences policy regardless of election outcomes is the Medicare Payment Advisory Commission, often referred to as MedPAC. Its forthcoming recommendations might threaten affordability and health benefits for older Americans.
MedPAC is intended to be an advisory body, mainly generating reports and conducting calculations. Yet, its findings frequently serve as groundwork for Congressional actions, media narratives, and questionable budget assumptions that affect the health insurance affordability for the over 30 million seniors enrolled in Medicare Advantage.
Therefore, it’s crucial for President Trump and Republican leaders in Congress to approach MedPAC’s claims regarding Medicare Advantage (MA) with skepticism. This is particularly relevant nowadays as some parts of the Centers for Medicare and Medicaid Services (CMS) rely on MedPAC for justification, claiming “flat” spending on MA next year—despite evidence that healthcare costs continue to rise.
If the CMS’s recent proposals in an advanced rate notice are put into practice, millions of seniors may face higher healthcare costs next year, alongside cuts to various benefits. Holding back growth rates amid escalating expenses could have serious repercussions. This could translate to reduced options for supplemental benefits like dental, vision, and prescription drug coverage, along with an increase in out-of-pocket expenses for seniors.
For years, MedPAC has pushed a narrative that Medicare Advantage, developed under Republican reforms, costs taxpayers more than traditional fee-for-service Medicare. However, many studies contradict this assertion. MedPAC routinely cites factors like coding strength, favorable selection, and payment disparities to argue that private plans are overcompensated, advocating for payment reductions or program restructuring.
What doesn’t get equal attention is that these “overpayment” claims are not fixed truths. They stem from estimates based on assumptions that are often disputed by researchers and industry experts. A shift in assumptions could narrow the perceived gaps significantly, and different interpretations of coding differences will yield varied results. Nonetheless, MedPAC’s estimates tend to be presented as definitive facts, a portrayal reinforced by some mainstream media and certain lawmakers opposed to MA.
A recent editorial in the Wall Street Journal criticized MedPAC’s position, suggesting that the committee is being influenced by progressives who are dubious of the private market. This concern is echoed in MedPAC’s staffing and membership history.
Indeed, a notable portion of MedPAC’s team and committee members is linked to the Democratic Party, registered as Democratic voters, or have a history of supporting Democratic candidates and committees. This undermines the idea that the commission operates neutrally or solely on technical expertise. Medicare Advantage was intended to foster competition and consumer choice, principles not fully embraced by many on the left.
This perspective is significant. Analysts often believe that private plans can’t outperform government-run models, leading them to interpret ambiguous data in a way that reinforces their skepticism.
However, surveys consistently show that Medicare Advantage beneficiaries are largely satisfied with their coverage. Reports indicate around 95% of MA enrollees appreciate the quality of care provided. Seniors value coordinated care and additional benefits—like out-of-pocket protections—that traditional Medicare often lacks. All of these could be at risk if funding remains stagnant, leading to fewer choices among doctors and specialists.
Currently, Medicare Advantage enrollment represents over half of all Medicare beneficiaries, and this growth isn’t by chance. Seniors are actively choosing these plans. However, they might soon face significant cuts to their benefits, particularly with midterm elections on the horizon focusing on affordability.
The foundation of Medicare Advantage is the belief that older adults deserve choices and that competition can enhance care quality. It would be both a political and policy misstep to undermine this based on contentious estimates, especially given that seniors themselves largely express satisfaction.
If there are weaknesses in Medicare Advantage, they should be addressed. Improvements in risk adjustment are welcome. Yet, we must not allow an advisory body in Washington, heavily influenced by a liberal policy perspective suspicious of market-based reforms, to erode one of the most well-regarded aspects of modern Medicare while negatively impacting the affordability of health insurance for seniors.
President Trump’s main goal is to challenge the entrenched, unelected power structures in Washington. He’s often discussed dismantling the so-called “deep state,” a bureaucracy that influences policy no matter the electoral outcomes.
The key question for Republicans is straightforward: Do we stand with the unelected experts who view Medicare Advantage with skepticism, or do we support the 35 million seniors who rely on it and are facing impending cuts and price increases?
